Oramed Pharmaceuticals Inc. (ORMP) Stock Score, Valuation & Financial Research
Oramed Pharmaceuticals Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 65/100.
Quick answer for ORMP
Oramed Pharmaceuticals Inc. currently has a Wall Street Score of 65/100. The stored market price is $4.66. Its financial score is 52/100. Its valuation score is 100/100. These figures are a research snapshot, not a buy or sell recommendation.
What Oramed Pharmaceuticals Inc. does
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
ORMP financial snapshot
- Wall Street Score:
- 65/100
- Current price:
- $4.66
- Market capitalization:
- $190.7M
- Revenue:
- $0
- Net income:
- $110.0M
- Free cash flow:
- $-11.1M
- Cash:
- $13.2M
- Total debt:
- $761K
- EPS:
- 1.53
- P/E ratio:
- 3.0x
- Financial score:
- 52/100
- Valuation score:
- 100/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -1.0%.
- Free cash flow is $-11.1M, showing cash burn in the current stored period.
- The balance sheet shows $13.2M of cash versus $761K of total debt, leaving more cash than debt.
- The current research record carries a missing revenue history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 52/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research ORMP
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.